FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	urden								

0.5

hours per response

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

												.,,						
1. Name and Address of Reporting Person* <u>DUBOW JORDAN</u>				<u>A</u>	2. Issuer Name and Ticker or Trading Symbol AVADEL PHARMACEUTICALS PLC [AVDL]								5. Relationship of Reporting Person(s) to Issu (Check all applicable) Director 10% Ov					ner
(Leet)	and (Final) (Mindle)				3. Date of Earliest Transaction (Month/Day/Year)								fficer (elow)	give title Other (s below)		oecify		
(Last) (First) (Middle)												Chief Medical Officer						
BLOCK 10-1, BLANCHARDSTOWN					04/11/2019													
CORPORATE PARK, BALLYCOOLIN					4. If Amendment, Date of Original Filed (Month/Day/Year)						6	6. Individual or Joint/Group Filing (Check Applicable						
(Street)				_ _	i ranonament, bate or original rilea (month/bay/rear)							Line)						
DUBLIN L2 15												, , ,						
			_								Form filed by More than One Reporting Person							
(City)	(S	tate)	(Zip)															
			bla I. Nan Da				. ^ -		:		f au Da		U O	!				
			ble I - Non-De		_			quirea, D	-		-							
1. Title of Security (Instr. 3) 2. Transidate (Month/I					Year)	2A. Deemed Execution Date, if any (Month/Day/Year		, Transaction Disposed Code (Instr. 5)			ies Acquir Of (D) (Ins	ed (A) or str. 3, 4 ar	1 and Securitie Beneficia Owned F		es Form ally (D) of Following (I) (II		: Direct II Indirect E str. 4) C	7. Nature of Indirect Beneficial Ownership
								Code	' A	Amount	(A) o	Price	Tra		ed ction(s) 3 and 4)			Instr. 4)
			Table II - Der					uired, Dis					y Own	ed				
				1	, can		_	, .			1							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr.) 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title at of Securi Underlyi Derivativ (Instr. 3 a	Deriv Secu	ative rity	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		piration te	Title	Amount or Number of Share	s		(Instr. 4)	on(a)		
Stock Option (right to buy)	\$1.44	04/11/2019		A		340,000		(1)	04/1	/11/2029	ADSs ⁽²⁾	340,00	0 \$1	.44	340,00	00	D	

Explanation of Responses:

- 1. Options become exercisable as to 85,000 ADSs on each of the first four anniversaries after the 04/11/2019 grant date.
- 2. The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value \$0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts.

Remarks:

Remarks to Table I: No non-derivative securities are beneficially owned.

/s/ Phillandas T. Thompson as attorney-in-fact for Jordan

Dubow, M.D.

dan 04/30/2019

<u>Dubow, 141.D.</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.